Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

TerminatedOBSERVATIONAL
Enrollment

21,000

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions
Venous Thromboembolism
Trial Locations (1)

08807

Sanofi U.S., Bridgewater

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY